Bettering the Lives of People Impacted by Kidney Disease John Butler, CEO January 2025 1 NASDAQ: AKBA Cautionary note on forward-looking statements 3 Leading commercial-stage company focused on kidney disease Vafseo® (vadadustat) launched as treatment for anemia due to chronic kidney disease for adult patients on dialysis ~$1billion U.S. market opportunity in dialysis patient population1 Statements in this presentation regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectatio ...

John Butler, CEO January 2025 1 NASDAQ: AKBA Cautionary note on forward-looking statements Statements in this presentation regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: Akebia's plans, strategies and prospects for its business; Akebia's plans with resp ...

Akebia Therapeutics (AKBA) 2025 Conference June 05, 2025 08:45 AM ET Speaker0 Welcome to Jefferies twenty twenty five global healthcare conference. My name is Roger Song, one of the senior analysts cover Simica Biotech in The US. It's my pleasure to have the fireside chat with our first of the day company, Akebia Therapeutics. We have our CFO, CBO, Eric, and then Chief Commercial Officer, Nick here with us. Welcome gentlemen. Great. Thanks, Roger. Awesome. All right. Let's just kick this off and then we kno ...

Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat) The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that compared the safety and efficacy of vadadustat with darbepoetin alfa in adult patients with CKD-related anemia. Data from the pre-specified analyses for the U.S. patient subgroup demonstrate that among patients with DD-CKD, safety and efficacy of vadadustat and darbepoetin alfa in the ...

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

Vadadustat clinical data on display for nephrologists and healthcare providersCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the 62nd European Renal Association (ERA) Congress on June 4-7, 2025, both virtually and live in Vienna. Akebia-supported presentations at ERA Congress 2025: A Win-Ratio Analysis of the Cardiovascu ...

Akebia Therapeutics (AKBA) FY 2025 Conference May 20, 2025 02:30 PM ET Speaker0 Right. So I guess we can get started here. So my name is Matthew Caulfield. I'm a senior biotech analyst here at H. C. Wainwright, and we're very excited to be welcoming Akebia Therapeutics. We're joined by John Butler, CEO, and also Nick Grund, chief commercial officer. So thank you very much for joining us today, guys. Speaker1 Thanks for having us, Matt. Great to you. Speaker0 So maybe to start off, you could maybe give us an ...

Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.08 per share when it actually produced a loss of $0.10, delivering a surprise of -25%.Over the las ...

Akebia Therapeutics (AKBA) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate CommunicationsJohn Butler - CEO, President & DirectorNicholas Grund - SVP & COOErik Ostrowski - SVP, CFO & Chief Business OfficerNicholas Grund - SVP & COOLes Sulewski - VP - Biotech Equity Research Conference Call Participants Roanna Ruiz - Senior Managing Director, Biotechnology AnalystNone - AnalystRoger Song - Senior Equity Research AnalystAllison Bra ...

Akebia Therapeutics (AKBA) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 and thank you for standing by. Welcome to the Acaeus First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker for today, Ms. Mercedes Carrasco, Senior Di ...